|Mr. Anthony S. Marucci M.B.A.
|Founder, President, CEO & Director
|Dr. Tibor Keler
|Founder, Chief Scientific Officer & Executive VP
|Mr. Sam Martin
|Senior VP, CFO, Secretary & Treasurer
|Dr. Margo Heath-Chiozzi M.D.
|Senior Vice President of Regulatory Affairs
|Dr. Diane C. Young M.D.
|Senior VP & Chief Medical Officer
|Prof. Joseph P. Schlessinger Ph.D.
|Co-Founder & Member of Scientific Advisory Board
|Ms. Sarah Cavanaugh
|Senior Vice President of Corporate Affairs & Administration
|Senior Director of Investor Relations & Corporate Communications
|Mr. Freddy A. Jimenez Esq.
|Senior VP & General Counsel
|Dr. Ronald A. Pepin
|Chief Business Officer & Senior VP
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. It has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Celldex Therapeutics, Inc.’s ISS governance QualityScore as of 1 February 2024 is 1. The pillar scores are Audit: 2; Board: 2; Shareholder rights: 1; Compensation: 5.